Vimpat

lacosamide

Tablet (oral) · NDA 022253

Last listed protection ended

April 28, 2026

The FDA listed 1 exclusivity for Vimpat, and this is the day the last one ended. It is not the date a generic goes on sale.

Patents and exclusivities